Gut dysbiosis linked to worse disease status in AxSpA ⭐️higher dysbiosis associated w/ worse EvalGlobal, ASDAS-CRP, BASDAI, BASFI, VAS pain ⭐️comparing dysbiosis vs. non-dysbiosis group - significant difference in BASDAI, BASFI, EvalGlobal Abs#POS0237 #EULAR2021 @RheumNow

#EULAR2021 POS0227 recs all patients try subQ MTX before bDMARD. Mirza et al: ⬆️ efficacy & ⬇️side effects with subQ. May not be for all pts, but subQ ⬆️ efficacy than high-dose PO MTX. ⬇️ GI side effects, but ⬆️ ulcers/hair loss (use folate/leucovorin for this) @RheumNow

Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its Faculty.

SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatment algorithm in axPsA (as the predominant domain?) Poster #POS1045 #EULAR2021 @RheumNow

PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhi

• http://ow.ly/Q4wp50F3uTN

#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg

• https://bit.ly/3fS5SJX

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow & its Faculty.

Who responds better to bDMARDs in RA, PsA & SpA? Men, women or equal? POS0208 #EULAR2021 @RheumNow @eular_org